论文部分内容阅读
目的研究不同类型珠蛋白生成障碍性贫血并发缺铁性贫血(IDA)儿童各项血液学指标的变化,为指导临床筛查和治疗奠定理论依据。方法择取2012年2月至2015年3月就诊的360例贫血患儿,通过DNA诊断法及铁代谢筛查法确定患儿的基因类型及其相应铁代谢指标情况,并将患儿分为地贫组160例、地贫合并IDA组170例和IDA组30例,同时选择30名健康儿童为对照组,检测上述各组的血液学指标并进行统计学分析。结果与对照组比较,各组地贫患儿的红细胞相关参数均有差异性(P均<0.05),其中α地贫轻型及β地贫杂合子型患儿表现小红细胞低色素症状,而α地贫Hb H型及β地贫纯合子型患儿表现中重度贫血症状;与非合并IDA组相比,合并IDA型患儿的血液学参数均有统计学意义(P均<0.05),且部分且铁代谢指标有显著性差异(P<0.05);与男性组患儿相比,女性组患儿合并IDA及IDA型的患病例数普遍高于男性组患儿例数。结论应密切关注正常儿童及地贫患病儿童的各项血液学指标变化,为贫血症的有效预防和临床筛查奠定理论基础。
Objective To study the changes of hematological indexes in different types of children with idiopathic thalassemia associated with iron deficiency anemia (IDA), and to lay a theoretical foundation for clinical screening and treatment. Methods A total of 360 children with anemia who were treated from February 2012 to March 2015 were enrolled in this study. The genotype and corresponding iron metabolism index of children were determined by DNA diagnostic method and iron metabolism screening method. The children were divided into 160 in Thalassemia group, 170 in IDA group and 30 in IDA group. Thirty healthy children were selected as control group, and the hematological indexes of the above groups were tested and statistically analyzed. Results Compared with the control group, the erythrocyte related parameters of children with thalassemia were significantly different in all groups (all P <0.05). The children with mild thalassemia and heterozygotes of β thalassemia showed hypoproliferation, Hypothyroidism Hb H type and β-thalassemia homozygous children showed moderate and severe anemia; compared with non-IDA group, the hematological parameters of children with IDA type were statistically significant (all P <0.05), and (P <0.05). Compared with the male group, the prevalence of IDA and IDA in the female group was generally higher than that in the male group. Conclusions Careful attention should be paid to the changes of hematological indexes in children with normal children and children with thalassemia and to lay a theoretical foundation for the effective prevention and clinical screening of anemia.